Linked Life Data

18084952

Source:http://linkedlifedata.com/resource/pubmed/id/18084952

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2007-12-18
pubmed:abstractText
The detection of disease recurrence and treatment monitoring pose high demands on diagnostic modalities. Whereas serum marker levels in most cases allow an assessment of tumor load and a respective response to therapy, they do not confer information on the localization of disease. Although this diagnostic gap is filled by imaging modalities, most techniques based on morphology will come to a limit when fibrotic tissue alterations have to be differentiated from viable tumor tissue in case of suspected recurrence or when residual masses after chemotherapy have to be assessed. The metabolic information on tumor cells gained by fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging appears not only to be more sensitive and reliable in this respect, but also appears to allow assumptions on response to therapy, and ultimately on patient prognosis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:issn
0080-0015
pubmed:author
pubmed:issnType
Print
pubmed:volume
177
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
105-10
pubmed:dateRevised
2008-2-13
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Detection of disease recurrence and monitoring of therapy.
pubmed:affiliation
Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Klinik für Nuklearmedizin, Germany.
pubmed:publicationType
Journal Article